Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9935086 | 0.85 | TAAR1 (0.52) | TAAR1MEN1KMT2ANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL696798 | 0.84 | TAAR1 (0.51) | TAAR1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL17540637 | 0.81 | KMT2A (0.44) | MEN1KMT2ALMNA | |
| SCHEMBL17540701 | 0.79 | CTSB (0.38) | ALDH1A1KDM4E | |
| SCHEMBL31107125 | 0.78 | SPR (0.72) | SPRTAAR1CNR1NPC1RAB9A | |
| SCHEMBL12720882 | 0.78 | SPR (0.72) | SPRTAAR1CNR1NPC1RAB9A | |
| SCHEMBL20052592 | 0.78 | MEN1 (0.43) | TAAR1MEN1KMT2ALMNA | |
| SCHEMBL17540700 | 0.77 | KMT2A (0.38) | TAAR1MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL16444681 | 0.77 | NPC1 (0.56) | TAAR1CNR1MEN1KMT2ANPC1 | |
| SCHEMBL31173308 | 0.76 | MTNR1A (0.67) | TAAR1CNR1NPC1RAB9AMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106470994-B | For treating the substituted pyrazine of CNS disease simultaneously [2,1-A] isoquinilone derivatives | 豪夫迈·罗氏有限公司 | 2019-09-24 | — | — | CN | disclosed |
| US-10316036-B2 | Substituted pyrazino[2,2-a]isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-06-11 | — | — | US | disclosed |
| EP-3186250-B1 | SUBSTITUTED PYRAZINO[2,1-A]ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2018-04-18 | — | — | EP | disclosed |
| US-20180037582-A1 | SUBSTITUTED PYRAZINO[2,2-a]ISOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-9828374-B2 | Substituted pyrazino[2,2-a]isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-11-28 | — | — | US | disclosed |
| EP-3186250-A1 | SUBSTITUTED PYRAZINO[2,1-A]ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. Hoffmann-La Roche AG (CH) | 2017-07-05 | — | — | EP | disclosed |
| US-20170145010-A1 | SUBSTITUTED PYRAZINO[2,2-a]ISOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| CN-106470994-A | For treating substituted pyrazine simultaneously [2,1 A] isoquinilone derivatives of CNS disease | 豪夫迈·罗氏有限公司 | 2017-03-01 | — | — | CN | disclosed |
| WO-2016030306-A1 | SUBSTITUTED PYRAZINO[2,1-A]ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145010-A1 | SUBSTITUTED PYRAZINO[2,2-a]ISOQUINOLINE DERIVATIVES | HCRTR2, CYP11B2, CYP1A2 | SPR 3524/4885TAAR1 437/4885CNR1 74/4885 |
| US-20180037582-A1 | SUBSTITUTED PYRAZINO[2,2-a]ISOQUINOLINE DERIVATIVES | HCRTR2, HCRTR1, CYP11B2 | SPR 3647/4885TAAR1 199/4885CNR1 27/4885 |
| US-10316036-B2 | Substituted pyrazino[2,2-a]isoquinoline derivatives | HCRTR2, HCRTR1, CYP11B2 | SPR 3647/4885TAAR1 199/4885CNR1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.